Emergency Management

in Predictive Molecular Pathology Laboratories:
an International Experience

Find out more on
http://emergence.medicacom.it/

on line from October 31, 2020

About

Predictive molecular pathology in the time of COVID-19 in Europe*
In the time of COVID-19, predictive molecular pathology laboratories must still timely select oncological patients for targeted treatments. However, the need to respect social distancing measures may delay results generated by laboratory-developed tests based on sequential steps a long hands-on time. Laboratory workflows should now be simplified.*

Key messages

- The COVID-19 outbreak modifies laboratory organisation to **limit personnel number** and **working hours**.

- Despite these limitations, in our laboratories, oncological **patients** have **timely been tested** for targeted treatments.

- This public health emergency underlines even more the concept that predictive molecular pathology should be practised in advanced laboratories by **highly trained staff**, even if fully automated procedures are employed.

Team sharing experiences

Scientific advisors

Prof. Giancarlo Troncone *Department of Public Health, University of Naples Federico II, Naples, Italy*

Prof. Umberto Malapelle *Department of Public Health, University of Naples Federico II, Naples, Italy*

Faculty

Prof. Massimo Barberis *Histopathology and Molecular Diagnostics Unit. European Institute of Oncology IRCCS, Milan,I taly*

Prof. Matteo Fassan *Surgical Pathology Unit, Department of Medicine, University of Padua, Padua, Italy*

Prof. Fernando Schmitt *Molecular Pathology Unit, IPATIMUP, University of Porto, Porto, Portugal*

Prof. Sabine Merkelbach-Bruse *Institute of Pathology, University of Cologne, Cologne, Germany*

Prof. Hans Brunnström *Department of Clinical Sciences, Division of Oncology and Pathology, Lund University, Lund, Sweden*

Prof. Paul Hofman *Department of Pathology, Nice Pasteur Hospital, University Côte d'Azur, Nice, France*